Newsrooom | Medtronic | 2017 Press Releases

2017 Press Releases


201720162015201420132012
Search News Releases
 
DateTitle  
04/26/17Five-Year Data from the Medtronic ENGAGE Registry Demonstrate Durable, Consistent, and Proven Outcomes in Real-World Setting
Presented at Charing Cross, Five-Year Clinical Data from Global ENGAGE Registry  Support Endurant II's Market-Leading Position Worldwide DUBLIN and LONDON - April 26, 2017 - Medtronic plc (NYSE:MDT) today reported its Endurant® II abdominal aortic aneurysm (AAA) stent graft system continues to demonstrate long-term durability and consistent outcomes in a real-world setting. The five-year ENGAGE global registry data were presented for the first time at the 2017 Charing Cross Symposium in London... 
Download PDFPrinter Friendly Version
04/25/17New Medtronic Data Demonstrate Clinical and Quality of Life Benefits for VenaSeal Closure System in Venous Reflux Disease Patients
Three-Year VeClose Trial and One-Year WAVES Study Data Presented at Charing Cross DUBLIN and LONDON - April 25, 2017 - Medtronic plc (NYSE: MDT) today announced three-year outcomes from the VeClose U.S. pivotal clinical trial and one-year data from the WAVES study. Both results were presented by Kathleen Gibson, M.D., of Lake Washington Vascular in Bellevue, Wash., at the 2017 Charing Cross Symposium in London. The new data demonstrate the clinical and quality of life benefits of the Medtronic... 
Download PDFPrinter Friendly Version
04/25/17Medtronic Drug-Coated Balloon (DCB) Demonstrates Consistent Results in Two New Analyses of Complex PAD Patients
DUBLIN and LONDON - April 25, 2017 - Medtronic plc (NYSE: MDT) today reinforced consistent results for its IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) with two new sub-analyses from the IN.PACT Global Study in patients with peripheral artery disease (PAD). The new data were reported at the annual 2017 Charing Cross Symposium (CX) in London, one of the world's largest educational meetings specializing in vascular and endovascular disease management. Sub-Analysis in Patients with Complex Le... 
Download PDFPrinter Friendly Version
04/24/17Medtronic Announces Most Advanced StealthStation(TM) for Neurosurgery
New Platform to Offer Flexibility, Ease of Use, Improved Registration and Advanced Visualization for Custom Procedural Workflows   DUBLIN and LOS ANGELES - April 24, 2017 - Medtronic plc (NYSE:MDT) today launched its new StealthStation(TM) technology at the American Academy of Neurological Surgeons (AANS) annual conference in Los Angeles. StealthStation technology has been a mainstay in neurosurgery suites for the past 25 years, being used in more than 2.25 million procedures.   With the new St... 
 Printer Friendly Version
04/20/17Data Highlight Medtronic Vascular Innovations at Charing Cross 2017
New Data from the Global ENGAGE Registry, IN.PACT Admiral Global Study, and VeClose Study Among Key Presentations LONDON and DUBLIN - April 20, 2017 - Medtronic plc (NYSE: MDT) today announced key clinical studies for its leading vascular interventional portfolio will be featured at the annual 2017 Charing Cross Symposium (CX), one of the world's largest educational meetings specializing in vascular and endovascular disease management, in London from April 25-28, 2017. This year, more than 40 ... 
Download PDFPrinter Friendly Version
04/20/17Medtronic Brain Therapies Business Sponsors Parkinson's Unity Walk
DUBLIN - April 20, 2017 - Medtronic plc (NYSE: MDT) announced its sponsorship of the 23rd Parkinson's Unity Walk which will be held on April 22, 2017, in New York City. Beginning at 8:30 a.m. EDT, thousands of Parkinson's patients, caregivers and supporters will walk the 1.4 mile course through New York's Central Park. Medtronic will be on site at the Unity Walk to provide information on deep brain stimulation (DBS), a therapy that is shown to reduce some of the symptoms associated with Parkinso... 
Download PDFPrinter Friendly Version
04/18/17FDA Designates Medtronic Worldwide Voluntary Field Action on HVAD(TM) System Controllers and DC Adapters as Class I Recall
DUBLIN - April 18, 2017 - Medtronic plc (NYSE: MDT) announced today that the U.S. Food and Drug Administration (FDA) has classified the company's recently initiated voluntary field action related to its HVAD(TM) System Controllers (serial numbers lower than CON300000) and DC Adapters (all serial numbers for product code 1435) as a Class I recall.   Medtronic began notifying clinicians outside of the United States in March 2017 about updated HVAD System Controllers and DC Adapters that were deve... 
Download PDFPrinter Friendly Version
04/18/17Medtronic Signs Definitive Agreement to Divest a Portion of Its Patient Monitoring & Recovery Division to Cardinal Health for $6.1 Billion
DUBLIN - April 18, 2017 - Medtronic plc (NYSE: MDT) today announced that it has entered into a definitive agreement with Cardinal Health Inc. (NYSE: CAH) to sell its Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses within the Patient Monitoring & Recovery (PMR) division of its Minimally Invasive Therapies Group (MITG). The transaction is expected to close in Medtronic's second quarter of its fiscal year 2018, subject to receipt of customary regulatory approvals and sa... 
Download PDFPrinter Friendly Version
04/13/17Medtronic Syncs Garmin® Activity Tracker Data Directly into Remote Patient Monitoring Mobile Platform
Data from Garmin vívofit® Series Now Syncs to Medtronic Care Management Services NetResponse® Mobile Application to Help Track Patient Health at Home DUBLIN and OLATHE, Kan. - April 13, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, and Garmin International Inc., a unit of Garmin Ltd. (NASDAQ: GRMN), today announced the integration of Garmin wearable device data directly into Medtronic Care Management Services' (MCMS) remote patient monitoring platform. Medtronic was t... 
Download PDFPrinter Friendly Version
04/12/17Medtronic Seeks Runners from Around the World Benefitting from Medical Technology for 2017 Global Champions Team
Applications now open: www.medtronic.com/globalchampions Selected runners receive entry and travel to the Medtronic Twin Cities Marathon or Medtronic TC 10 Mile in October 2017 Up to 20 people will be selected for the 2017 Global Champions team DUBLIN - April 12, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced applications are now open for the 2017 Medtronic Global Champions team. Medtronic Global Champions is a new program that recognizes athletes... 
Download PDFPrinter Friendly Version
04/06/17Clinical Trial of Medtronic Heart Pump Delivers Positive Results with Less-Invasive Implant Procedure
HVAD(TM) System is a Mechanical Pump that Circulates Blood Throughout the Body in Patients with Advanced Heart Failure. DUBLIN and SAN DIEGO - April 6, 2017 - Preliminary results from the Medtronic plc (NYSE:MDT)-sponsored HVAD LATERAL(TM) study were presented today as a late breaking clinical trial during the 2017 International Society for Heart and Lung Transplantation (ISHLT) Scientific Meeting in San Diego. Patients with end-stage heart failure, who have not responded to standard medical man... 
Download PDFPrinter Friendly Version
04/06/17Medtronic Announces Voluntary Worldwide Recall of its StrataMR(TM) Adjustable Valves and Shunts
DUBLIN - April 6, 2017 - Medtronic plc (NYSE: MDT) today announced that on February 22, 2017 it notified customers of a voluntary recall of all unused units of the StrataMR(TM) adjustable valves and shunts. These products are manufactured and marketed by Medtronic's Neurosurgery business, which is part of the Brain Therapies division of the company's Restorative Therapies Group. This recall only applies to StrataMR adjustable valves and shunts and does not apply to Strata(TM) II or Strata(TM) NS... 
 Printer Friendly Version
04/05/17Study Shows Medtronic Left Ventricular Assist Devices Have Positive Results at One Year in Patients Seeking Long-Term LVAD Therapy
Data Presented in Late-Breaking Presentation at ISHLT 2017 DUBLIN and SAN DIEGO - April 5, 2017 - Medtronic plc (NYSE:MDT) today announced results of the ENDURANCE Supplemental trial in a late-breaking clinical trial session of the 2017 International Society for Heart and Lung Transplantation (ISHLT) Scientific Meeting in San Diego. The study evaluated the company's HVAD(TM) System as a destination (long-term) therapy for patients needing heart pumps (left ventricular assist devices, or LVAD) wh... 
Download PDFPrinter Friendly Version
04/05/17Medtronic Announces Worldwide Voluntary Field Corrective Action For Newport(TM) HT70 and Newport(TM) HT70 Plus Ventilators
DUBLIN - April 5, 2017 - Medtronic (NYSE: MDT) is notifying customers worldwide of a voluntary field corrective action for all its Newport HT70 and Newport HT70 Plus ventilators manufactured since 2010. The voluntary field corrective action is being conducted following reports that the ventilator may reset spontaneously during normal operation, without an accompanying alarm. The reported incidence of this condition is approximately one (1) reset in every seven million hours of ventilation. Follo... 
Download PDFPrinter Friendly Version
03/30/17Medtronic Initiates Global Trial Evaluating Cryoablation to Treat Persistent Atrial Fibrillation
DUBLIN - March 30, 2017 - Medtronic plc (NYSE: MDT) today announced first enrollments in the STOP Persistent AF clinical trial. The trial will evaluate the safety and effectiveness of a pulmonary vein isolation-only (PVI) strategy for treating patients with persistent atrial fibrillation (AF), using the Arctic Front Advance(TM) Cardiac CryoAblation Catheter. John Harding, M.D., Doylestown Hospital in Doylestown, Penn., treated the first patient enrolled in the trial. STOP Persistent AF is a pr... 
Download PDFPrinter Friendly Version
03/24/17New Guidelines Support Use of Cardiac Monitoring for Patients with Unexplained Fainting
American College of Cardiology, American Heart Association and Heart Rhythm Society Jointly Issue First-Ever Syncope Guidelines that Reinforce Benefits of Continuous Cardiac Monitoring DUBLIN - March 24, 2017 - Newly published guidelines from the American College of Cardiology (ACC), the American Heart Association (AHA), and the Heart Rhythm Society (HRS) recommend the use of cardiac monitors for evaluating patients with unexplained fainting, called syncope. The "2017 ACC/AHA/HRS Guideline... 
Download PDFPrinter Friendly Version
03/22/17Medtronic Receives FDA Approval for CoreValve(TM) Evolut(TM) Pro Transcatheter Valve with Advanced Sealing
First-Ever Data at ACC.17 Confirms Safety and Efficacy of New Self-Expanding, Recapturable Heart Valve at 30-Days with High Survival, Low Stroke and Minimal Paravalvular Leak DUBLIN - March 22, 2017 - Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of the CoreValve(TM) Evolut(TM) PRO valve for the treatment of severe aortic stenosis for symptomatic patients who are at high or extreme risk for open heart surgery. The approval comes on the... 
Download PDFPrinter Friendly Version
03/21/17Medtronic Announces Pricing of $2 Billion of Senior Notes
DUBLIN - March 21, 2017 - Medtronic plc (NYSE: MDT) announced today that its wholly-owned subsidiary, Medtronic Global Holdings S.C.A. ("Medtronic Luxco"), has priced an offering of $1,000,000,000 principal amount of 1.700 percent senior notes due 2019 and $850,000,000 principal amount of 3.350 percent senior notes due 2027 (collectively, the "notes"). All of Medtronic Luxco's obligations under the notes will be fully and unconditionally guaranteed by Medtronic plc and Medtro... 
Download PDFPrinter Friendly Version
03/17/17Landmark SURTAVI Clinical Trial Shows Transcatheter Aortic Valve Replacement (TAVR) with the Self-Expanding Platform Performs as Well as Surgery in Intermediate Risk Severe Aortic Stenosis Patients
Late-Breaking SURTAVI Pivotal Clinical Trial Presented at ACC.17 and Published in NEJM Meets Primary Endpoint at Two Years DUBLIN and WASHINGTON, D.C. - March 17, 2017 - Medtronic plc (NYSE: MDT) today unveiled first-ever clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial, which was presented at the American College of Cardiology (ACC) 66th Annual Scientific Session and published simultaneously in The New England Journal of Medicine (NEJM)1. ... 
Download PDFPrinter Friendly Version
03/16/17Medtronic EVP & President Hooman Hakami to Speak at Oppenheimer Healthcare Conference
DUBLIN - March 16, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate in the Oppenheimer 27th Annual Healthcare Conference on Tuesday, March 21, 2017, in New York City. Hooman Hakami, executive vice president and group president of Medtronic's Diabetes Group, will answer questions about the company beginning at 8:35 a.m. EDT (7:35 a.m. CDT). A live audio webcast of the presentation will be available on March 21, 2017, by clicking on t... 
Download PDFPrinter Friendly Version
03/15/17New Partnership Between Medtronic and Atlas General Hospital Brings Advanced Surgical Technologies and Treatment Options to Serbia
Partnership to Focus on Improving Quality and Accessibility of Spine Care for Serbian Patients BELGRADE, Serbia -  March 15, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the signing of an Integrated Health Solutions (IHS) agreement with Atlas General Hospital  in Belgrade, Serbia. With this partnership, both companies will contribute to the improvement of the care experiences of thousands of spine patients at the Atlas General Hospital. As part of i... 
 Printer Friendly Version
03/14/17Medtronic Melody Transcatheter Pulmonary Valve First of Its Kind to Receive FDA Approval for Implantation in Failed Surgical Pulmonary Heart Valves
Newly Approved Indication in U.S. Expands Treatment Options to More Patients with Congenital Heart Disease DUBLIN - March 14, 2017 - Medtronic plc (NYSE: MDT) today announced that its Melody(TM)Transcatheter Pulmonary Valve (TPV) received approval from the United States Food and Drug Administration (FDA) for implantation in patients whose surgical bioprosthetic pulmonary heart valves have failed. Designed specifically for the pulmonic position, Melody TPV is the first transcatheter pulmonary v... 
Download PDFPrinter Friendly Version
03/14/17Medtronic Announces New Bone Cement Indication for Treating Sacral Fractures
Minimally Invasive Procedure Provides More Options for Osteoporotic Fracture Patients Suffering from Pain DUBLIN - March 14, 2017 - Medtronic plc (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of Kyphon(TM) Xpede Bone Cement for fixation of pathological fractures of the sacral vertebral body or ala using sacral vertebroplasty or sacroplasty - expanding the product's indications beyond treatment of vertebral fractures due to osteoporosi... 
Download PDFPrinter Friendly Version
03/13/17Medtronic Receives FDA Clearance for Reveal LINQ(TM) Insertable Cardiac Monitor (ICM) with TruRhythm(TM) Detection
Device Delivers Improved Accuracy and Streamlined Data for Clinicians DUBLIN - Mar. 13, 2017 - Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its Reveal LINQ(TM) Insertable Cardiac Monitor (ICM) with TruRhythm(TM) Detection, an advanced cardiac monitor offering improved accuracy to better identify abnormal heartbeats. Reveal LINQ ICM with TruRhythm Detection offers exclusive algorithms that result in a 95 percent reduction in false bradyc... 
Download PDFPrinter Friendly Version
03/10/17Medtronic Announces Medicare Reimbursement for the First and Only Leadless Pacemaker Available for Use in the U.S.
CMS Approves Required Studies for the Micra® Transcatheter Pacing System (TPS), the World's Smallest Pacemaker DUBLIN - Mar. 10, 2017 - Medtronic plc (NYSE: MDT) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has approved coverage for the Micra® Transcatheter Pacing System (TPS). This decision, effective immediately, follows the approval of two studies required to enable reimbursement through Medicare's policy of Coverage with Evidence Development (CED). In Janua... 
Download PDFPrinter Friendly Version
03/10/17Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2017
DUBLIN - Mar. 10, 2017 - The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2017 fourth quarter cash dividend of $0.43 per ordinary share, representing a 13 percent increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in June 2016.  Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 39 consecutive years. The dividend is p... 
Download PDFPrinter Friendly Version
03/09/17Medtronic Launches Below-The-Knee Clinical Study in Europe for Treatment of PAD Using New Drug-Coated Balloon Technology
First Procedure in Prospective, Randomized, Multi-Center Study Performed at Maria Cecilia Hospital in Italy DUBLIN - Mar. 9, 2017 - Medtronic plc (NYSE: MDT) today announced the launch of the IN.PACT(TM) BTK study to evaluate the effectiveness of using a drug-coated balloon (DCB) in patients with below-the-knee (BTK) peripheral arterial disease (PAD). This study will evaluate the IN.PACT 0.014 paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter. This is an investigatio... 
Download PDFPrinter Friendly Version
03/03/17Medtronic EVP & CFO Karen L. Parkhill to Speak at Barclays Healthcare Conference
DUBLIN - Mar. 3, 2017 - Medtronic plc  (NYSE:MDT), the global leader in medical technology, today announced it will participate in the Barclays Global Healthcare Conference on Wednesday, March 15, 2017, in Miami Beach, Florida. Karen Parkhill, executive vice president and chief financial officer of Medtronic, will make a presentation on the company beginning at 10:45 a.m. EDT (9:45 a.m. CDT). A live audio webcast of the presentation will be available on March 15, 2017, by clicking on the Inves... 
Download PDFPrinter Friendly Version
02/27/17New Analysis of Reverse Trial Shows Medtronic CRT Devices Cost-Effective, While Helping Patients with Mild Heart Failure Live Longer
JACC: HF Study Showcases Economic Value of Earlier Patient Access to Cardiac Resynchronization Therapy DUBLIN - Feb. 27, 2017 - Medtronic plc (NYSE:MDT) today announced an economic analysis of five-year data showing that patients with mild heart failure who get cardiac resynchronization therapy (CRT) devices early in their treatment live longer and that implanting these devices is cost-effective, compared to optimal medical therapy. Results from the REVERSE (REsynchronization reVErses Remodelin... 
Download PDFPrinter Friendly Version
02/27/17Medtronic EVP & RTG President Geoffrey S. Martha to Speak at Cowen Healthcare Conference
DUBLIN - Feb. 27, 2017 - Medtronic plc  (NYSE:MDT), the global leader in medical technology, today announced it will participate in the 37th Annual Cowen and Company Healthcare Conference on Tuesday, March 7, 2017, in Boston, Mass. Geoff Martha, executive vice president and president of the Medtronic Restorative Therapies Group (RTG), will answer questions about the company beginning at 8:40 a.m. EST (7:40 a.m. CST). A live audio webcast of the presentation will be available on March 7, 2017, ... 
Download PDFPrinter Friendly Version
02/24/17Medtronic Receives CE Mark for Its Next Generation Cardiac Resynchronization Therapy-Pacemakers
Suite of Smart Heart Failure Devices Offers More-Effective Pacing, Expanded MRI Access DUBLIN - Feb. 24, 2017 - Medtronic plc (NYSE:MDT) today announced that it has received CE (Conformité Européenne) Mark for a suite of quadripolar cardiac resynchronization therapy pacemakers (CRT-Ps) that also allow patients to receive MRI (magnetic resonance imaging) scans in either 1.5 or 3 Tesla (T) machines. This complete line of CRT-Ps, available in Europe in March, includes the Percepta(TM) Quad CRT-P M... 
Download PDFPrinter Friendly Version
02/23/17New Solitaire(TM) Stent Retriever Study Validates Outcomes and Real-World Application of Stroke Treatment Best Practices
Economic Study Finds Solitaire Stent Retriever Highly Cost-Effective DUBLIN and HOUSTON - Feb. 23, 2017 - Data presented today on Medtronic's (NYSE:MDT) Solitaire stent retriever at the International Stroke Conference (ISC) in Houston demonstrate that the results from the four pivotal randomized controlled trials - SOLITAIRE(TM) FR With the Intention For Thrombectomy as PRIMary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME), Endovascular Treatment for Small Core and Proximal Occ... 
Download PDFPrinter Friendly Version
02/21/17Medtronic Reports Third Quarter Financial Results
Revenue of $7.3 Billion Grew 5% as Reported; 6% at Constant Currency GAAP Diluted EPS of $0.59; Non-GAAP Diluted EPS of $1.12 GAAP Diluted EPS Declined 23%; Non-GAAP EPS Grew 10% at Constant Currency GAAP Operating Margin Declined 380 bps; Non-GAAP Operating Margin Improved 130 bps at Constant Currency GAAP Cash Flow from Operations of $2.1 Billion; Free Cash Flow of $1.8 Billion DUBLIN - February 21, 2017 - Medtronic plc (NYSE: MDT) today announced financial results for its third qua... 
Download PDFPrinter Friendly Version
02/17/17Medtronic Announces Japanese Regulatory Approval for Micra(TM) Transcatheter Pacing System (TPS)
DUBLIN - Feb. 17, 2017 - Medtronic plc (NYSE: MDT) today announced Japan regulatory approval for the world's smallest pacemaker, the Micra(TM) Transcatheter Pacing System (TPS). Japan's Pharmaceuticals and Medical Device Agency (PMDA) granted approval for Micra based on positive data from the Medtronic Micra TPS Global Clinical Trial, which enrolled 744 patients and evaluated the safety and efficacy of the device through a single-arm, multi-center study at 56 centers in 19 countries, including J... 
Download PDFPrinter Friendly Version
02/16/17FDA Approves Expanded Indication for Medtronic Freezor® Xtra Cryoablation Catheter
Demonstrated Safe and Effective for Treating Patients with Abnormal Heart Rhythm of AVNRT DUBLIN - Feb. 16, 2017 - Medtronic plc (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) has approved its Freezor® Xtra Cryoablation Catheter for treating patients with atrioventricular nodal re-entrant tachycardia (AVNRT), a life-threatening abnormal heart rhythm. The Freezor Xtra Catheter is a flexible, single-use device used to freeze cardiac tissue and block unnecessary electrical... 
Download PDFPrinter Friendly Version
02/16/17Medtronic Introduces Signia(TM) Stapling System, Innovative Surgical Stapler for Minimally Invasive Surgery
New Single-Handed Powered Stapling System Provides Real-time Feedback During Surgery1 DUBLIN - Feb. 16, 2017 - Delivering on its commitment to develop and expand minimally invasive surgery (MIS) technologies and capabilities, Medtronic plc (NYSE: MDT) announced the launch of its Signia(TM) Stapling System. The latest addition to the company's MIS portfolio, the Signia system provides surgeons with real-time feedback and automated responses to that real-time data. The Signia system includes Ada... 
Download PDFPrinter Friendly Version
02/15/17Medtronic's OsteoCool(TM) RF Ablation System Receives Expanded Indication for Palliative Treatment of Metastatic Bone Tumors
Minimally-Invasive Procedure Is First of its Kind in the U.S. to Bring Relief to Patients Suffering from Metastatic Bone Tumors DUBLIN - Feb. 15, 2017 - Medtronic plc (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded indication for the OsteoCool(TM) RF Ablation System. Originally cleared for use in the spine, the FDA now allows the marketing of the OsteoCool System for palliative treatment of metastases in all bony anatomy - such as ribs, sacr... 
Download PDFPrinter Friendly Version
02/13/17Medtronic EVP & President Michael J. Coyle to Speak at RBC Capital Markets Global Healthcare Conference
DUBLIN - Feb. 13, 2017 - Medtronic plc  (NYSE:MDT), the global leader in medical technology, today announced it will participate in the RBC Capital Markets 2017 Global Healthcare Conference on Thursday, February 23, 2017, in New York City. Mike Coyle, executive vice president and president of Medtronic's Cardiac and Vascular Group, will answer questions about the company, beginning at 10:30 a.m. EST (9:30a.m. CST). A live audio webcast of the presentation will be available on February 23, 2017... 
Download PDFPrinter Friendly Version
02/13/17Medtronic Expands Coronary Portfolio to Include New DxTerity(TM) Diagnostic Catheters and Suite of Tools for the Transradial Approach
Full Line of Innovative Transradial Products and Comprehensive Training Programs Reinforce Medtronic's Commitment to Optimizing the Treatment of Heart Disease DUBLIN - Feb. 13, 2017 - Medtronic plc (NYSE: MDT) today announced that its market-leading coronary portfolio will now include the DxTerity Diagnostic Angiography Catheter line and several transradial-specific products including the DxTerity TRA(TM), InTRAkit(TM) access kit and TRAcelet(TM) compression device, all of which received U.S. F... 
Download PDFPrinter Friendly Version
02/13/17Medtronic Announces New, Outcome-Based Learning Program
Introduces New Approach to Healthcare Education and Development Focused on Outcomes That Matter to Patients DUBLIN - Feb. 13, 2017 - Medtronic today announced the launch of Medtronic Impact in its Europe, Middle East & Africa region, which is part of the company's drive towards value-based healthcare (VBHC). Medtronic Impact introduces an entirely new approach to healthcare education and development, extending beyond traditional product and procedure training to delivering learning based on o... 
Download PDFPrinter Friendly Version
02/10/17Medtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2017
DUBLIN - Feb. 10, 2017 - Medtronic plc (NYSE: MDT) announced today that it will report financial results for its third quarter of fiscal year 2017 on Tuesday, February 21, 2017. A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at http://newsroom.medtronic.com. The news release will include summary financial information for the company's third quarter of fiscal year 2017, which ended on Friday, January 27, 2017. Medtronic will host a webc... 
Download PDFPrinter Friendly Version
02/09/17First Drug-Coated Balloon (DCB) Study Results in Japan Demonstrate Consistent Clinical Outcomes with Other Medtronic DCB Studies
New Data Recently Presented at LINC 2017 Represents the First Presentation of Clinical Results Comparing a DCB to Angioplasty in Japan DUBLIN - Feb. 9, 2017 - Medtronic plc (NYSE: MDT) today announced the one-year clinical outcomes from the MDT-2113 IN.PACT SFA Japan Trial. The data was recently presented by Osamu Iida, M.D., Kansai Rosai Hospital, Hyogo, Japan at the Leipzig Interventional Course (LINC) 2017 conference, and reinforced the consistent clinical outcomes obtained using Medtronic'... 
Download PDFPrinter Friendly Version
02/06/17Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors
Contract Award Continues Medtronic Care Management Services Veteran Support Initiated in 2011 DUBLIN - Feb. 6, 2017 - Medtronic plc (NYSE:MDT) today announced Medtronic Care Management Services (MCMS) is one of four vendors awarded a national contract from the U.S. Department of Veterans Affairs (VA) for Home Telehealth Technologies. MCMS has supplied the VA with telehealth solutions since 2011, and the new contract enables MCMS to continue supplying the VA with innovative remote patient monito... 
Download PDFPrinter Friendly Version
02/01/17Medtronic CardioInsight Mapping Solution Cleared by FDA
System First Used Commercially in U.S. This Week DUBLIN - Feb. 1, 2017 - Medtronic plc (NYSE: MDT) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the CardioInsight(TM) Noninvasive 3D Mapping System. The CardioInsight system is used to map a wide range of irregular heart rhythms in the upper and lower chambers of the heart, and provides electroanatomic 3D maps of the heart. The system was first used commercially in the U.S. by Vivek Reddy, M.D., director of cardiac arrh... 
Download PDFPrinter Friendly Version
01/26/17Medtronic Announces Medicare Coverage Decision for the First and Only Leadless Pacemaker Available for Use in the U.S.
CMS Decision Expands Patient Access to the Micra® Transcatheter Pacing System (TPS), the World's Smallest Pacemaker DUBLIN - Jan. 26, 2017 - Medtronic plc (NYSE: MDT) today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) will cover leadless cardiac pacemakers, as outlined in the agency's final National Coverage Determination (NCD). This decision will provide Medicare patient access to leadless pacemakers, consistent with the FDA-approved labeling for the devices, throug... 
Download PDFPrinter Friendly Version
01/26/17Medtronic Receives IDE Approval to Initiate Study of IN.PACT® Admiral® Drug-Coated Balloon for a New Indication in Patients with End-Stage Renal Disease
DUBLIN - Jan. 26, 2017 - Medtronic plc (NYSE: MDT) today announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to initiate a study of the IN.PACT® Admiral® drug-coated balloon (DCB) for a potential new indication in patients with end-stage renal disease. The randomized study will evaluate the IN.PACT Admiral DCB as a treatment for failing arteriovenous (AV) fistulas in these patients as compared to plain balloon angioplasty. The IDE appro... 
Download PDFPrinter Friendly Version
01/25/17Medtronic IN.PACT Admiral Drug-Coated Balloon Demonstrates Consistent Results in Asia and Belgium According to New Data Presented at LINC 2017
First Presentation of Results from Regional Cohorts of IN.PACT Global Study Reinforce Strong, Consistent and Safe Outcomes for PAD Patients  DUBLIN and LEIPZIG, Germany - Jan. 25, 2017 - Medtronic today presented new data at the Leipzig Interventional Course (LINC) 2017 conference supporting the IN.PACT® Admiral® drug-coated balloon (DCB) in patients with peripheral arterial disease (PAD). The real-world outcomes from regional cohorts of the IN.PACT Global Study in Asia and Belgium reinforce the... 
Download PDFPrinter Friendly Version
01/24/17First Procedure Performed in Medtronic MRI-Guided Laser Ablation Trial to Treat Common Form of Epilepsy
DUBLIN - Jan. 24, 2017 - Medtronic plc (NYSE: MDT) announced today that the first procedure using the Visualase(TM) MRI-Guided Laser Ablation System has been performed in the pivotal SLATE (Stereotactic Laser Ablation for Temporal Lobe Epilepsy) clinical trial at Mayo Clinic in Rochester, Minn. The SLATE clinical trial is designed to support the expanded indication of the currently marketed Visualase(TM) system for treatment of patients with drug-resistant mesial temporal lobe epilepsy (MTLE), t... 
Download PDFPrinter Friendly Version
01/24/17Medtronic Announces CE Mark for New Lower Profile HawkOne 6F Directional Atherectomy System
Expands Treatment Options for Patients in Europe with Peripheral Artery Disease Both Above and Below the Knee DUBLIN - Jan. 24, 2017 - Medtronic plc (NYSE: MDT) today announced CE (Conformité Européene) Mark approval for the HawkOne(TM) directional atherectomy system in a lower profile size for treating patients with peripheral artery disease (PAD). The new HawkOne 6 French (6F) provides an effective and easy-to-use treatment option for patients with PAD both above and below the knee with a si... 
Download PDFPrinter Friendly Version
01/17/17Medtronic Announces CE Mark and European Launch of Recaptureable TAVI System Now Available for Severe Aortic Stenosis Patients with Large Anatomies
Larger Device Offers Treatment to Patients Without a Previous TAVI Option DUBLIN - Jan. 17, 2017 - Medtronic plc (NYSE:MDT) today announced the CE (Conformité Européenne) mark and European launch of the CoreValve(TM) Evolut(TM) R 34 mm valve-the largest sized transcatheter aortic valve implantation (TAVI) system available in Europe. The new Evolut R 34 mm valve is approved for severe aortic stenosis patients who are at intermediate, high or extreme risk for surgery with an annulus size ranging ... 
Download PDFPrinter Friendly Version
01/03/17Medtronic CEO Omar Ishrak to Speak at J.P. Morgan Healthcare Conference
DUBLIN - Jan. 3, 2017 - Medtronic plc  (NYSE:MDT), the global leader in medical technology, today announced it will participate in the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017, in San Francisco.  Omar Ishrak, chairman and chief executive officer of Medtronic, will make a formal presentation on the company beginning at 10:00 a.m. PST (12:00 p.m. CST).  Shortly following the presentation, Ishrak and Karen Parkhill, executive vice president and chief financial offic... 
Download PDFPrinter Friendly Version
X